Ahmet Sezer

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 799 citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 706 citations · Full text

Medicine, Oncology, Pharmacology +17

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Mario Campone, Michelino De Laurentiis, Komal Jhaveri et al. · New England Journal of Medicine · 2025 · 94 citations

Medicine, Oncology, Pharmacology +17

Attributes of cancer patients admitted to the emergency department in one year

Sadık Muallaoğlu, Özlem Karagün, Mertsoylu Huseyin et al. · World Journal of Emergency Medicine · 2014 · 84 citations · Full text

Medicine, Emergency Medicine, Oncology +14

<p>Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy</p>

Erkan Topkan, Hüseyin Mertsoylu, Yurday Özdemir et al. · Cancer Management and Research · 2019 · 45 citations · Full text

Medicine, Oncology, Survival Analysis +15